{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:48:01Z","timestamp":1791110881514,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for patients with colorectal peritoneal metastases (CRPM). Patient selection is key to optimizing outcomes after CRS\/HIPEC. The aim of this study was to determine the prognostic value of ascites diagnosed on preoperative imaging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A prospective database of patients eligible for CRS\/HIPEC between 2010 and 2020 was retrospectively analyzed. The presence of ascites, postoperative complications, overall survival (OS), disease-free survival (DFS), and completeness of cytoreduction were assessed. Univariable and multivariable logistic regression was performed to identify independent predictors for outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 235 included patients, 177 (75%) underwent CRS\/HIPEC while 58 (25%) were not eligible for CRS\/HIPEC. In 42 of the 177 patients (24%) who underwent CRS\/HIPEC, ascites was present on preoperative computed tomography (CT) imaging. Peritoneal Cancer Index (PCI) score was significantly higher in patients with preoperative ascites compared with patients without (11 [range 2\u201330] vs. 9 [range 0\u201328], respectively; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.011) and complete cytoreduction was more often achieved in patients without ascites (96.3% vs. 85.7%; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.007). There was no significant difference in median DFS and OS after CRS\/HIPEC between patients with and without ascites {10 months (95% confidence interval [CI] 7.1\u201312.9) vs. 9 months (95% CI 7.2\u201310.8), and 25 months (95% 9.4\u201340.6) vs. 27 months (95% CI 22.4\u201331.6), respectively}.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Ascites on preoperative imaging was not associated with worse survival in CRS\/HIPEC patients with CRPM. Therefore, excluding patients from CRS\/HIPEC based merely on the presence of ascites is not advisable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-11718-7","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T19:03:34Z","timestamp":1650135814000},"page":"5256-5262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In Patients Undergoing CRS\/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival"],"prefix":"10.1245","volume":"29","author":[{"given":"Ibrahim","family":"Said","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Ubink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos S. G.","family":"Ewalds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna G. T.","family":"Arkesteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk M. W.","family":"Verheul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H. W.","family":"de Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena M.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas J. A.","family":"Bremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"de Reuver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,16]]},"reference":[{"issue":"5","key":"11718_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.8679","volume":"99","author":"J Segelman","year":"2012","unstructured":"Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699\u2013705.","journal-title":"Br J Surg"},{"issue":"13","key":"11718_CR2","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","volume":"20","author":"AM Kuijpers","year":"2013","unstructured":"Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20(13):4224\u201330.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"11718_CR3","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"11718_CR4","doi-asserted-by":"publisher","first-page":"06363","DOI":"10.1001\/jamasurg.2020.6363","volume":"156","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):06363.","journal-title":"JAMA Surg"},{"issue":"6","key":"11718_CR5","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/SLA.0000000000001593","volume":"263","author":"R Kwakman","year":"2016","unstructured":"Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016;263(6):1102\u201311.","journal-title":"Ann Surg"},{"issue":"1","key":"11718_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63\u20138.","journal-title":"J Clin Oncol."},{"issue":"6","key":"11718_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.amjsurg.2012.06.009","volume":"205","author":"EI Benizri","year":"2013","unstructured":"Benizri EI, Bereder JM, Rahili A, Bernard JL, Benchimol D. Ascites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer. Am J Surg. 2013;205(6):668\u201373.","journal-title":"Am J Surg"},{"issue":"5","key":"11718_CR8","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1245\/s10434-013-3224-y","volume":"21","author":"RW Randle","year":"2014","unstructured":"Randle RW, Swett KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014;21(5):1474\u20139.","journal-title":"Ann Surg Oncol"},{"key":"11718_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res"},{"issue":"2","key":"11718_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/bjs5.50250","volume":"4","author":"FMK Elekonawo","year":"2020","unstructured":"Elekonawo FMK, van Eden WJ, van der Plas WY, et al. Effect of intraperitoneal chemotherapy concentration on morbidity and survival. BJS Open. 2020;4(2):293\u2013300.","journal-title":"BJS Open"},{"issue":"13","key":"11718_CR11","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1245\/s10434-020-08844-5","volume":"27","author":"CA Munoz-Zuluaga","year":"2020","unstructured":"Munoz-Zuluaga CA, King MC, Diaz-Sarmiento VS, et al. Defining \u201ccomplete Cytoreduction\u201d after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC) for the histopathologic spectrum of appendiceal carcinomatosis. Ann Surg Oncol. 2020;27(13):5026\u201336.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"11718_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1159\/000490068","volume":"36","author":"FMK Elekonawo","year":"2019","unstructured":"Elekonawo FMK, van der Meeren MMD, Simkens GA, de Wilt JHW, de Hingh IH, Bremers AJA. Comparison of 2 perioperative management protocols and their influence on postoperative recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: standard parenteral nutrition, selective bowel decontamination and suprapubic catheters? Dig Surg. 2019;36(5):394\u2013401.","journal-title":"Dig Surg"},{"issue":"5","key":"11718_CR13","first-page":"518","volume":"111","author":"PA Clavien","year":"1992","unstructured":"Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111(5):518\u201326.","journal-title":"Surgery"},{"key":"11718_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.suronc.2020.02.010","volume":"33","author":"M Leimk\u00fchler","year":"2020","unstructured":"Leimk\u00fchler M, de Haas RJ, Pol VEH, et al. Adding diagnostic laparoscopy to computed tomography for the evaluation of peritoneal metastases in patients with colorectal cancer: a retrospective cohort study. Surg Oncol. 2020;33:135\u201340.","journal-title":"Surg Oncol"},{"key":"11718_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s12885-021-08168-x","volume":"21","author":"MP Engbersen","year":"2021","unstructured":"Engbersen MP, Rijsemus CJV, Nederend J, et al. Dedicated MRI staging versus surgical staging of peritoneal metastases in colorectal cancer patients considered for CRS-HIPEC; the DISCO randomized multicenter trial. BMC Cancer. 2021;21:464.","journal-title":"BMC Cancer"},{"issue":"1","key":"11718_CR16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12885-019-5545-0","volume":"19","author":"KP Rovers","year":"2019","unstructured":"Rovers KP, Bakkers C, Simkens GAAM, et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer. 2019;19(1):390.","journal-title":"BMC Cancer"},{"issue":"2","key":"11718_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1245\/ASO.2004.05.009","volume":"11","author":"P Shen","year":"2004","unstructured":"Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11(2):178\u201386.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"11718_CR18","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.3892\/ol.2016.4403","volume":"11","author":"HT Men","year":"2016","unstructured":"Men HT, Gou HF, Liu JY, et al. Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: a retrospective study from a single center. Oncol Lett. 2016;11(5):3501\u20137.","journal-title":"Oncol Lett"},{"issue":"2","key":"11718_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/MJT.0b013e3181ff7a8b","volume":"19","author":"S Singhal","year":"2012","unstructured":"Singhal S, Baikati KK, Jabbour II, Anand S. Management of refractory ascites. Am J Ther. 2012;19(2):121\u201332.","journal-title":"Am J Ther"},{"issue":"1","key":"11718_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jso.25453","volume":"120","author":"C Hodge","year":"2019","unstructured":"Hodge C, Badgwell BD. Palliation of malignant ascites. J Surg Oncol. 2019;120(1):67\u201373.","journal-title":"J Surg Oncol"},{"issue":"7","key":"11718_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/DCR.0000000000000589","volume":"59","author":"B Trilling","year":"2016","unstructured":"Trilling B, Cotte E, Vaudoyer D, et al. Intraperitoneal-free cancer cells represent a major prognostic factor in colorectal peritoneal carcinomatosis. Dis Colon Rectum. 2016;59(7):615\u201322.","journal-title":"Dis Colon Rectum"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11718-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T20:09:28Z","timestamp":1656619768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11718-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,16]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["11718"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11718-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,16]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}